Dulaglutide
Also known as: Trulicity
Key Facts: Dulaglutide
- Category
- Weight Loss
- FDA Status
- FDA Approved
- Clinical Status
- FDA Approved - Type 2 diabetes
- Administration
- Subcutaneous injection weekly
- Typical Dose
- 1.5-4.5 mg weekly
- Frequency
- Once weekly
- Evidence Level
- FDA Approved
- Duration
- Long-term / chronic use
What to Expect
An FDA-approved weekly GLP-1 receptor agonist for type 2 diabetes. Fused to an Fc antibody fragment for extended duration of action.
Mechanism of Action
Dulaglutide consists of two GLP-1 analogs linked to a modified human IgG4 Fc fragment. This structure extends half-life to about 5 days, allowing weekly dosing. Works through standard GLP-1 receptor activation.
Research Summary
AWARD program showed significant A1C reduction and weight loss. REWIND trial demonstrated cardiovascular benefits in broader diabetic population. Generally shows 3-5% weight loss in trials.
Dosing Information
Typical Dosingⓘ
Community experience
1.5-4.5 mg weekly
0.75-4.5 mg weekly
Once weekly
FDA-approved as Trulicity. Titrate from 0.75 mg. Convenient once-weekly dosing.
Research Dosingⓘ
Scientific studies
FDA-approved dosing
Doses from Studies
0.75mg weekly (starting)
1.5mg weekly
3.0mg, 4.5mg weekly (higher doses)
Duration
Long-term / chronic use
Administration
Subcutaneous injection weekly
Timing & Administration
Best Time to Take
Before bed or morning (fasted)
Follow specific peptide protocol
Food Recommendation
Take on empty stomach
Why This Timing?
GH-related peptides work best on an empty stomach to maximize growth hormone release.
Possible Side Effects
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●Nausea
- ●Diarrhea
- ●Vomiting
- ●Abdominal pain
- ●Injection site reactions
- ●Hypoglycemia (with insulin/sulfonylureas)
- ●Pancreatitis
- ●Gallbladder problems
- ●BOXED WARNING: Thyroid C-cell tumors
- ●FDA approved (Trulicity)
References
Related Peptides
Peptides commonly compared with Dulaglutide or used in similar applications.
Semaglutide
FDAA GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management. One of the most effective pharmaceutical weight loss interventions available.
Weight LossTirzepatide
FDAA dual GIP/GLP-1 receptor agonist representing the next generation of incretin-based therapies. Shows superior weight loss compared to semaglutide in head-to-head trials.
Weight LossLiraglutide
FDAAn FDA-approved GLP-1 receptor agonist for type 2 diabetes and chronic weight management. The predecessor to semaglutide with daily dosing.
Weight LossExenatide
FDAThe first GLP-1 receptor agonist approved for diabetes. Derived from Gila monster saliva. Available in twice-daily and weekly formulations.
Weight LossRetatrutide
Clinical TrialsA triple agonist targeting GLP-1, GIP, and glucagon receptors. Represents the next evolution beyond dual agonists like tirzepatide, showing unprecedented weight loss in trials.
Weight LossOrforglipron
Clinical TrialsAn oral non-peptide GLP-1 receptor agonist. Could provide injection-free alternative to semaglutide and tirzepatide.
Weight LossWant updates on Dulaglutide research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.
Educational Information Only
This information is provided for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare providers before making any decisions about peptides or other substances. The protocols listed reflect doses observed in research studies, not recommendations.